The drug candidates include novel bispecific antibodies and engineered cytokines with a heterodimer Fc domain, which enables rapid design, simplified development, and stable structure. Nine XmAb bispecific antibodies and one engineered cytokine are being evaluated in phase I clinical studies conducted by Xencor and its partners:

• CD3 bispecific antibodies (CD123 x CD3, CD20 x CD3, SSTR2 x CD3) that contain a tumor associated antigen and a second binding domain targeted to CD3, an activating receptor on T cells
• Tumor microenvironment activator bispecific antibodies incorporating Xencor's Xtend technology for increased half-life (XmAb20717, XmAb22841, XmAb23104)
• Cytokines built with Xencor's XmAb bispecific Fc domain for improved potency and Xtend technology for increased half-life (XmAb24306, co-developed with Genetech)

Xencor has committed to funding and supporting these studies over an initial five-year term.

Xencor, Atreca to work on T cell-based cancer therapies
Biopharmaceutical company Xencor and biotechnology company Atreca have entered into a license agreement to research, develop, and commercialize T cell-engaging...

CNS Pharma partners with MD Anderson
Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center...